News

Designed and discovered by Isis Pharmaceuticals, iCo-007 is a second-generation antisense drug targeting c-Raf kinase for the treatment of DME and diabetic retinopathy. In consideration for the technology

Mylan claimed that for patients in whom the drug is used for more than 2-3 weeks, periodic reevaluation is recommended to determine whether there is a continuing need.

Shrink claimed that utilising its rapid prototyping solutions, three dimensional biochips can be developed with precise specifications compared to current production methods that require many hours, day or

The fluidization of powders, using compressed air through a porous media to make flow like liquids, is a process used in many industries. Applications for powder fluidization are

Nutra Pharma said that Nyloxin Rx is a prescription pain reliever clinically proven to treat Stage 3 (severe) chronic pain. Unlike Stage 2 pain, which interferes with both

inVentiv Clinical said that PPC is the company’s Asia Pacific partner with its headquarters located in Taiwan. PPC is into serving the pharmaceutical, biotechnology, generic drug and medical

The Debride WH-1 topical treatment product was developed by McCoy Enterprises, the same organisation responsible for creation of the buccal mucosa drug delivery system licensed to Spring Creek

Eli Lilly and Galapagos initiated their alliance to develop new medicines for the treatment of osteoporosis in 2008. The alliance agreement provides Lilly access to 12 of Galapagos’

Blue Medical said that on placement of the stent a predetermined load of Paclitaxel will be delivered to the vessel wall to support the vessel in adapting to